

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, Mr. Wei Jiawei (韋家威) (“**Mr. Wei**”) has been nominated as an executive Director of the Company. Such appointment is subject to the approval by the Shareholders at the upcoming annual general meeting of the Company. The term of Mr. Wei will be the same as the term of the current session of the Board.

The biographical details of Mr. Wei are set out below:

Mr. Wei, aged 44, joined our Company in September 2020 and was appointed as the deputy general manager in November 2020. He is primarily responsible for sales management of our Company.

Mr. Wei has extensive experience in the field of marketing and sale of medical devices. Between September 2005 to December 2008, he worked in the BSC International Medical Trading (Shanghai) Corporation Limited (波科國際醫療貿易(上海)有限公司). From July 2008 to July 2018, Mr. Wei was first a regional sales manager in Ev3 Medical Devices (Beijing) Corporation Limited (醫偉司安醫療器材(北京)有限公司) and then promoted to the manager of its national new business development department of Covidien Healthcare International Trading (Shanghai) Corporation Limited (柯惠醫療器材國際貿易(上海)有限公司), both companies being the subsidiaries of Medtronic plc. He was a deputy general manager of sales of Jiangsu Nico Medical Technology Corporation Limited (江蘇尼科醫療器械有限公司) from August 2018 to August 2020.

Mr. Wei obtained his bachelor’s degree in chemical pharmaceutical technology from East China University of Science and Technology (華東理工大學) in the PRC in July 1999.

A circular, together with a notice convening the annual general meeting, containing, inter alia, details of the proposed appointment of Mr. Wei as an executive Director will be dispatched to the shareholders of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Subject to the approval by the Shareholders of Mr. Wei’s appointment as an executive Director, Mr. Wei will enter into a service contract with the Company for a term of service running from the date of his appointment until the end of the term of the current session of the Board. He shall be eligible for re-election upon the expiry of his term of office. Pursuant to such proposed service contract, as an executive Director, Mr. Wei will not receive any director remuneration from the Company.

Mr. Wei does not and has not held any directorships in any other listed public companies in the last three years prior to the date of this announcement, of which the securities are listed on any securities market in Hong Kong or overseas, and nor does he have other major appointments and professional qualifications. Furthermore, Mr. Wei does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company, nor does he have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above and to the best of the knowledge, information and belief of the directors having made all reasonable enquiries, there are no other matters in relation to the proposed appointment of Mr. Wei that need to be brought to the attention of the shareholders of the Company or disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, March 28, 2022

As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.